Systematic review reveals Betulinic acid's impact on apoptosis and oxidative stress in cancer cells and normal tissues, suggesting therapeutic potential.
Betulinic acid (BA), a naturally occurring pentacyclic triterpenoid, exhibits remarkable bidirectional regulatory effects on apoptosis, demonstrating pro-apoptotic activity in cancer cells while protecting normal cells from oxidative stress and apoptosis. This systematic review synthesizes decade-long research to elucidate BA's multifaceted mechanisms across apoptosis-related pathways. In malignant cells, BA induces caspase-dependent apoptosis through both extrinsic pathways mediated by FADD via death receptor activation and intrinsic mechanisms involving ROS accumulation, Bcl-2 family-mediated mitochondrial dysfunction, and ERS-triggered PERK activation. Concurrently, it suppresses PI3K-Akt and NF-κB survival signaling while activating AMPK/mTOR-autophagy crosstalk and p53-dependent DNA damage responses. Paradoxically, BA protects normal tissues by enhancing antioxidant defenses through Nrf2/SOD activation, inhibiting pro-inflammatory TNF-α/NF-κB signaling, and stabilizing mitochondrial integrity. Key to its therapeutic potential is the context-dependent modulation of critical nodes that balance apoptosis initiation and cytoprotection. Structural derivatives and nano-formulations further enhance BA's tumor selectivity and bioavailability. By mapping BA's pleiotropic interactions within apoptotic networks, this review highlights its unique capacity to function as a precision therapeutic agent, offering dual cytostatic and cytoprotective benefits. These insights position BA as a promising candidate for cancer therapy development, warranting further investigation into pathway crosstalk and clinical translation strategies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: